Clinical Trial Update: Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours [Phase 2]

View source ↗

Summary

Phase II open-label study of AZD9291 (osimertinib) in EGFR-mutant, T790M-positive non-small cell lung cancer after progression on prior EGFR TKIs. Results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-06-07